300142 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Walvax Biotechnology Co., Ltd. engages in the research, development, production, and sale of biopharmaceutical products. Its products include Bivalent human papillomavirus vaccine, 13-valent pneumococcal polysaccharide conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine, Haemophilus influenzae type b conjugate vaccine, Group A and Group C meningococcal polysaccharide conjugate vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company was founded on January 16, 2001 and is headquartered in Kunming, China.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
300142 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company